Prestige Competitors

Stocks . Korea . 
Stock . Prestige Biologics Co
334970 Stock  KRW 5,330  360.00  6.33%   
Prestige Biologics competes with Sungchang Autotech, Woori Technology, Jeju Air, Jeju Beer, and Tway Air; as well as few others. The company operates under Healthcare sector and is part of Biotechnology industry. Analyzing Prestige Biologics competition allows you to expand the diversification possibilities of your existing portfolios and to get a better perspective on locking in new positions. Investors sometimes prefer comparable analysis of Prestige Biologics to its intrinsic valuation because they are able to contrast its competitors on a relative basis. Check out Prestige Biologics Correlation with its peers.
You can use the Comparative Equity Analysis module to analyze the advantages of investing in your portfolio's related equities across multiple sectors and thematic ideas. Please use the input box below to enter symbols for particular investments you would like to analyze. With the equity comparison module, you can estimate the relative effect of Prestige Biologics competition on your existing holdings.
  
Hype
Prediction
LowEstimatedHigh
5,6865,6905,694
Details
Intrinsic
Valuation
LowRealHigh
5,0685,0726,259
Details
Please note, it is not enough to conduct a financial or market analysis of a single entity such as Prestige Biologics. Your research has to be compared to or analyzed against Prestige Biologics' peers to derive any actionable benefits. When done correctly, Prestige Biologics' competitive analysis will give you plenty of quantitative and qualitative data to validate your investment decisions or develop an entirely new strategy toward taking a position in Prestige Biologics.

Prestige Biologics Competition Correlation Matrix

Typically, diversification allows investors to combine positions across different asset classes to reduce overall portfolio risk. Correlation between Prestige Biologics and its competitors represents the degree of relationship between the price movements of corresponding stocks. A correlation of about +1.0 implies that the price of Prestige and its corresponding peer move in tandem. A correlation of -1.0 means that prices move in opposite directions. A correlation of close to zero suggests that the price movements of assets are uncorrelated; in other words, the historical price movement of Prestige Biologics does not affect the price movement of the other competitor.
Click cells to compare fundamentals   Check Volatility   Backtest Portfolio
High positive correlations   
046120
+ 0.55
032820
048530
+ 0.44
276730
048530
+ 0.4
080470
091810
+ 0.32
080470
089590
+ 0.31
080470
276730
+ 0.31
089590
  
High negative correlations   
091810
- 0.47
276730
048530
- 0.25
007070
276730
- 0.24
032820
007070
- 0.15
091810
007070
- 0.14
080470
046120
- 0.12
080470

Risk-Adjusted Indicators

There is a big difference between Prestige Stock performing well and Prestige Biologics Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Prestige Biologics' multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.
All Fundamental Data

Prestige Biologics Competitive Analysis

The better you understand Prestige Biologics competitors, the better chance you have of utilizing it as a position in your portfolios. From an individual investor's perspective, Prestige Biologics' competitive analysis can cover a whole range of metrics. Some of these will be more critical depending on who you are as an investor and how you react to market volatility. However, if you are locking your investment sandscape to a long-term horizon, comparing the fundamental indicator across Prestige Biologics' competition over several years is one of the best ways to analyze its investment potential.
    
 Better Than Average     
    
 Worse Than Peers    View Performance Chart
334970 080470 032820 089590 276730 091810 007070 048530 046120
 6.33 
 5,330 
Prestige
 0.65 
 3,845 
Sungchang
 2.84 
 2,225 
Woori
 3.49 
 9,780 
Jeju
 3.67 
 3,250 
Jeju
 2.16 
 2,945 
Tway
 0.22 
 23,150 
007070
 1.98 
 5,440 
INtRON
 4.54 
 2,315 
Orbitech
Market Volatility
(90 Days Market Risk)
Very steady
Very steady
Very steady
Very steady
Very steady
Very steady
Very steady
Very steady
Very steady
Market Performance
(90 Days Performance)
Very Weak
Very Weak
Weak
Weak
Weak
Insignificant
Modest
Very Weak
Weak
Odds of Financial Distress
(Probability Of Bankruptcy)
Below Average
Low
Low
Below Average
Low
Below Average
Low
Low
Low
Current Valuation
(Equity Enterprise Value)
Over Valued
Over Valued
Over Valued
Fairly Valued
Over Valued
Over Valued
Fairly Valued
Fairly Valued
Over Valued
Buy or Sell Advice
(Average Analysts Consensus)
Not Available
Not Available
Not Available
Not Available
Not Available
Not Available
Not Available
Not Available
Not Available
Trade Advice
(90 Days Macroaxis Advice)
Sell
Strong Sell
Strong Sell
Sell
Strong Sell
Strong Sell
Cautious Hold
Cautious Hold
Strong Sell
Current Ratio
N/A
1.09
0.75
N/A
N/A
N/A
N/A
3.71
1.26
Net Asset
206.77 B
115.37 B
148.1 B
1.27 T
N/A
735.05 B
N/A
153.37 B
136.94 B
Profit Margin
N/A
0.0206
-0.0613
-0.5
N/A
-0.45
N/A
0.34
-0.16
EBITDA
(12.84 B)
10.4 B
3.44 B
(205.94 B)
N/A
(80.73 B)
N/A
11.82 B
6.32 B
Current Valuation
555.64 B
91.57 B
359.4 B
1.55 T
N/A
661.06 B
N/A
734.71 B
188.1 B
Operating Margin
N/A
0.0271
-0.0145
-0.54
N/A
-0.34
N/A
0.31
0.0355
Price To Book
N/A
N/A
N/A
15.25
N/A
17.04
N/A
N/A
N/A
Retained Earnings
N/A
31.1 B
(36.03 B)
N/A
N/A
N/A
N/A
2.09 B
(5.44 B)
Current Asset
N/A
63.73 B
25.62 B
N/A
N/A
N/A
N/A
17.15 B
17.91 B
Beta
N/A
1.51
0.46
1.19
N/A
1.6
N/A
0.45
1.26
Number Of Employees
N/A
209
109
2.71 K
N/A
2
N/A
93
456
Shares Outstanding
N/A
7.3 M
95.63 M
76.92 M
N/A
160.12 M
N/A
29.88 M
23.46 M
Cash Flow From Operations
(25.87 B)
9.29 B
8.83 B
(83.74 B)
N/A
35.1 B
N/A
16.47 B
(6.29 B)
Annual Yield
N/A
0.0054
N/A
0.0375
N/A
N/A
N/A
N/A
N/A
Total Debt
71.54 B
8.61 B
11.24 B
213.94 B
N/A
N/A
N/A
16.13 B
9.55 B
Return On Equity
-53.64
14.23
11.16
-7.4
N/A
-3.14
N/A
11.16
-24.13
Z Score
1.2
4.6
7.2
3.6
N/A
N/A
N/A
9.6
6.6
Return On Asset
N/A
0.0198
-0.0037
-0.13
N/A
-0.0958
N/A
0.0519
0.0139
Book Value Per Share
N/A
5713.23
N/A
N/A
N/A
N/A
N/A
2283.83
1681.22
Current Liabilities
N/A
58.17 B
30.02 B
N/A
N/A
N/A
N/A
2.86 B
13.38 B
Total Asset
206.77 B
115.37 B
148.1 B
1.27 T
N/A
735.05 B
N/A
153.37 B
136.94 B
Debt To Equity
N/A
0.51
153.7
N/A
N/A
N/A
N/A
10.9
40.9
Target Price
N/A
N/A
N/A
16696.0
N/A
3100.0
N/A
16400.0
N/A
Last Dividend Paid
N/A
N/A
N/A
650.0
N/A
N/A
N/A
N/A
N/A
Shares Owned By Institutions
N/A
N/A
0.66
8.8
N/A
1.15
N/A
8.1
0.68
Market Capitalization
198.91 B
53.73 B
135.79 B
1.3 T
N/A
492.38 B
N/A
265.62 B
105.11 B
Price To Earning
N/A
35.69
N/A
N/A
N/A
N/A
N/A
313.17
N/A
Price To Sales
N/A
0.33
2.82
2.08
N/A
0.82
N/A
9.32
1.56
Net Income
(39.38 B)
4.56 B
3.58 B
(272.28 B)
N/A
(156.24 B)
N/A
9.73 B
5.52 B
Earnings Per Share
N/A
N/A
N/A
-584.0
N/A
N/A
N/A
N/A
N/A
Shares Owned By Insiders
N/A
52.11
7.83
39.49
N/A
50.72
N/A
15.72
15.8
Revenue
3.23 B
144.58 B
52.14 B
273.08 B
N/A
214.4 B
N/A
29.31 B
78.18 B
Working Capital
N/A
5.56 B
(4.4 B)
N/A
N/A
N/A
N/A
14.29 B
4.52 B
Cash And Equivalents
36.77 B
4.65 B
27.94 B
N/A
N/A
N/A
N/A
75.17 B
14.79 B
Cash Per Share
N/A
924.83
158.44
N/A
N/A
N/A
N/A
N/A
327.4
Gross Profit
(2.88 M)
13.9 B
14.28 B
(227.07 B)
N/A
(109.21 B)
N/A
26.45 B
(959.53 M)
Day Typical Price
5463.33
3816.67
2236.67
9583.33
3215.0
2993.33
23150.0
5483.33
2351.67
Accumulation Distribution
0.0765
242.11
184205.0
31247.85
15032.9
185843.0
0.0256
3125.4
5841.03
Market Facilitation Index
440.0
0.0118
0.0
0.0017
6.0E-4
1.0E-4
600.0
0.0036
0.0012
Daily Balance Of Power
(0.82)
0.2381
(0.57)
0.4521
0.6571
(0.29)
0.0833
(0.44)
(0.85)
Period Momentum Indicator
(360.00)
25.0
(65.00)
330.0
115.0
(65.00)
50.0
(110.00)
(110.00)
Rate Of Daily Change
0.94
1.01
0.97
1.03
1.04
0.98
1.0
0.98
0.95
Day Median Price
5530.0
3802.5
2242.5
9485.0
3197.5
3017.5
23150.0
5505.0
2370.0
Price Action Indicator
(380.00)
55.0
(50.00)
460.0
110.0
(105.00)
25.0
(120.00)
(110.00)
Relative Strength Index
28.82
59.4
50.82
48.35
54.33
44.1
41.66
54.42
48.44
Coefficient Of Variation
(4,060)
(2,447)
2097.56
1280.11
(953.20)
1415.18
966.71
(753.66)
138941.08
Mean Deviation
2.71
1.52
2.9
1.38
3.34
3.27
1.39
1.31
1.97
Jensen Alpha
(0.16)
(0.06)
0.1327
0.1039
(0.65)
0.2831
0.1683
(0.26)
(0.06)
Total Risk Alpha
(0.71)
(0.52)
(0.48)
(0.18)
(1.37)
(0.46)
(0.13)
(0.56)
(0.45)
Sortino Ratio
N/A
N/A
0.0163
0.0059
N/A
0.0475
0.029
N/A
(0.05)
Downside Variance
N/A
N/A
9.13
2.33
N/A
16.21
3.82
N/A
8.27
Standard Deviation
3.66
2.47
3.92
1.88
5.01
4.65
1.88
1.82
2.64
Kurtosis
1.24
4.82
1.69
0.9432
4.91
2.35
0.6036
3.21
0.7691
Potential Upside
6.13
4.04
7.38
3.49
9.07
7.78
4.03
2.84
4.47
Treynor Ratio
(0.20)
0.2969
0.5127
0.5346
(0.58)
1.14
1.48
(2.63)
(0.02)
Maximum Drawdown
18.21
16.6
20.5
9.12
22.32
26.84
9.17
10.61
14.11
Variance
13.42
6.12
15.34
3.52
25.08
21.64
3.53
3.31
6.98
Market Risk Adjusted Performance
(0.19)
0.3069
0.5227
0.5446
(0.57)
1.15
1.49
(2.62)
(0.01)
Risk Adjusted Performance
(0.01)
(0.02)
0.0445
0.0656
(0.07)
0.0624
0.085
(0.1)
0.0077
Skewness
0.8703
(1.16)
1.06
0.7564
0.0118
0.7487
0.3759
1.24
0.2122
Semi Deviation
N/A
N/A
2.83
1.41
N/A
3.7
1.6
N/A
2.59
Information Ratio
(0.06)
(0.1)
0.0125
0.0048
(0.13)
0.0411
0.0302
(0.21)
(0.05)
Value At Risk
(4.93)
(4.09)
(4.82)
(2.49)
(6.13)
(7.82)
(2.88)
(2.68)
(3.40)
Expected Short fall
N/A
N/A
(3.87)
(1.61)
N/A
(4.05)
(1.59)
N/A
(1.97)
Downside Deviation
N/A
N/A
3.02
1.53
N/A
4.03
1.96
N/A
2.87
Semi Variance
N/A
N/A
8.0
1.98
N/A
13.68
2.55
N/A
6.71

Prestige Biologics Competition Performance Charts

Five steps to successful analysis of Prestige Biologics Competition

Prestige Biologics' competitive analysis is the process of researching and evaluating its competitive landscape. It provides an understanding of the strengths, weaknesses, opportunities, and threats (SWOT) faced by Prestige Biologics in relation to its competition. Prestige Biologics' competition analysis typically involves several steps, including:
  • Identifying the key players in the market: This involves identifying the major competitors of Prestige Biologics in the market, both direct and indirect, as well as new entrants and disruptive technologies.
  • Assessing the strengths and weaknesses of each competitor: This involves evaluating each competitor's strengths and weaknesses in areas such as product offerings, market share, brand recognition, financial performance, and distribution channels.
  • Understanding the competitive environment: This involves evaluating the regulatory environment, economic conditions, and other factors that may impact Prestige Biologics' competitive landscape.
  • Identifying opportunities and threats: This involves using the information gathered during the analysis to identify opportunities and threats to Prestige Biologics, and developing a strategy to address them.
  • Evaluating the competitive landscape: This involves understanding the competitive dynamics of the market, such as pricing, marketing, and distribution strategies, as well as analyzing the competitive advantage of each competitor.
Competitive analysis is an essential tool for businesses to stay ahead of the competition and can be used to inform decision-making and strategy development. By understanding the competitive landscape and staying informed about the activities of competitors, a company can make more informed decisions and improve its overall performance.

Complement your Prestige Biologics position

In addition to having Prestige Biologics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Real Estate Thematic Idea Now

Real Estate
Real Estate Theme
Fama and French investing themes focus on testing asset pricing under different economic assumptions. The Real Estate theme has 61 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Real Estate Theme or any other thematic opportunities.
View All  Next Launch

Other Information on Investing in Prestige Stock

Prestige Biologics financial ratios help investors to determine whether Prestige Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Prestige with respect to the benefits of owning Prestige Biologics security.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY